We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLRN
1701
DELISTED
ACELYRIN
SLRN
| $23.8K | ﹤0.01% |
+5,386
| New | +$25.2K |
|
1702
Capital City Bank Group
CCBG
$866M
| $23.6K | ﹤0.01% |
830
-1,091
| -57% | -$29.6K |
|
|
ARCH
1703
DELISTED
Arch Resources, Inc.
ARCH
| $23.1K | ﹤0.01% |
152
| – | – |
|
1704
Cathay General Bancorp
CATY
$4.17B
| $22.7K | ﹤0.01% |
601
-4
| -0.7% | -$145 |
|
1705
News Corp Class B
NWS
$18.1B
| $22.6K | ﹤0.01% |
795
+626
| +370% | +$16.7K |
|
1706
Cytek Biosciences
CTKB
$636M
| $22.5K | ﹤0.01% |
4,033
-154
| -4% | -$925 |
|
1707
OraSure Technologies
OSUR
$239M
| $22.3K | ﹤0.01% |
5,245
-50,260
| -91% | -$255K |
|
1708
Alpha and Omega Semiconductor
AOSL
$749M
| $22.1K | ﹤0.01% |
+592
| New | +$15.6K |
|
1709
MaxCyte
MXCT
$123M
| $22.1K | ﹤0.01% |
5,626
-1,114
| -17% | -$4.79K |
|
|
UMH
1710
UMH Properties
UMH
$1.33B
| $21.1K | ﹤0.01% |
1,319
-431
| -25% | -$6.71K |
|
|
LGF.B
1711
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $21K | ﹤0.01% |
+2,454
| New | +$22K |
|
1712
Sony
SONY
$140B
| $21K | ﹤0.01% |
1,235
+85
| +7% | +$1.41K |
|
|
CMA
1713
DELISTED
Comerica
CMA
| $20.4K | ﹤0.01% |
400
-2,797
| -87% | -$143K |
|
1714
Capital Bancorp
CBNK
$595M
| $20.3K | ﹤0.01% |
992
| – | – |
|
1715
Acadia Pharmaceuticals
ACAD
$4.61B
| $20.2K | ﹤0.01% |
1,245
-7,403
| -86% | -$119K |
|
1716
Campbell Soup
CPB
$6.37B
| $20.1K | ﹤0.01% |
444
-56
| -11% | -$2.5K |
|
1717
First Solar
FSLR
$21.7B
| $19.8K | ﹤0.01% |
+88
| New | +$19.2K |
|
1718
B&G Foods
BGS
$257M
| $19.6K | ﹤0.01% |
2,421
| – | – |
|
|
HLVX
1719
DELISTED
HilleVax
HLVX
| $19.5K | ﹤0.01% |
1,350
-368
| -21% | -$5.06K |
|
|
TTSH
1720
DELISTED
Tile Shop Holdings
TTSH
| $19K | ﹤0.01% |
2,745
| – | – |
|
1721
Addus HomeCare
ADUS
$2.16B
| $18.9K | ﹤0.01% |
163
-13
| -7% | -$1.39K |
|
1722
Oxford Industries
OXM
$444M
| $18.8K | ﹤0.01% |
188
+15
| +9% | +$1.58K |
|
|
EVRI
1723
DELISTED
Everi Holdings
EVRI
| $18.5K | ﹤0.01% |
2,201
-217
| -9% | -$1.77K |
|
1724
Sally Beauty Holdings
SBH
$1.47B
| $18.4K | ﹤0.01% |
1,717
-53,429
| -97% | -$587K |
|
1725
BP
BP
$121B
| $18.3K | ﹤0.01% |
508
+32
| +7% | +$1.2K |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.